Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 5 Clinical trials for therapies aiming to deactivate CAFs

From: Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects

Agents

Comb

Cancer

Phase

Trial number

Outcomes

Refs.

ATRA

Chemo

PDAC

I

NCT03307148

Prolonged median OS

[443]

ATRA

ICI

Melanoma

Ib/II

NCT03200847

ORR (71%)

[444]

Seocalcitol

Mono

Pancreatic

II

Futility

[448]

Vitamin D

Chemo

CRC

II

NCT01516216

Futility

[449]

Minnelide

Mono

Pancreatic

II

NCT03117920

Minnelide

Mono

GIST

I

NCT01927965

Minnelide

Chemo

PDAC

I

NCT05557851

  1. PDAC, pancreatic ductal adenocarcinoma; CRC, colorectal cancer; GIST, gastrointestinal stromal tumour. OS, overall survival; ORR, objective/overall response rate